Back to Archived News
Positron Recieves US Patent on Tech-Assist
Thursday, February 18, 2010
Indianapolis, IN -- Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the U.S. Patent and Trademark office has allowed for issuance a Patent on Positron’s Tech-Assist™. The Tech-Assist™, invented under the direction of John A. Zehner, a nuclear pharmacist, dramatically reduces exposure to the worker while injecting radiopharmaceuticals into patients when performing Positron Emission Tomography (PET) imaging studies. Currently utilized at several institutions to reduce or eliminate radiation exposure, the Tech-Assist™ can accept single syringes from a nuclear pharmacy or can be combined with other Positron equipment such as the Nuclear Pharm-Assist® to dispense unit doses from a vial. The Tech-Assist™ fully compliments the Attrius™, Positron’s cardiac and whole body PET scanner.
"The Tech-Assist™ is an affordable solution to reduce or eliminate exposure caused by the process of injecting PET isotopes," stated John A. Zehner, COO and Radiation Safety Officer of Positron. "Many new F-18 agents have the potential to increase exposure to the worker, reducing the exposure from a new agent will allow that agent to become widely utilized. F-18 agents are expected to significantly increase in use for multiple applications, including Cardiac and whole body bone imaging. This patent provides Positron the protection to grow this market segment and demonstrates Positron’s dedication to improving Nuclear Medicine through innovation."
Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
Back to Archived News